These drugs fall within two categories: human GLP-1 backbone agents (that is, albiglutide, dulaglutide, liraglutide and semaglutide) and exendin-4 backbone agents (that is, exenatide, lixisenatide and tirzepatidethe latter activating both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors) 1
No insurance is required, and the medication is HSA/FSA eligible, making the transition financially accessible for most patients
A practical approach keeps your heaviest sets at the same weight for fewer total sets
There is also a serotonergic component
For Canadians seeking significant body composition changes, Retatrutide represents the most promising peptide currently in late-stage development, with protein intake of 80-100g daily being essential for optimal muscle preservation during treatment